Neuren Pharmaceuticals Limited (NURPF) Income Statement
Neuren Pharmaceuticals Limited Income Statement
Last quarter (Q2 2026), Neuren Pharmaceuticals Limited's total revenue was $33.16M, an increase of 36.29% from the same quarter last year. In Q2, Neuren Pharmaceuticals Limited's net income was $4.85M. See Neuren Pharmaceuticals Limited’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 64.63M | $ 213.24M | $ 231.93M | $ 14.55M | $ 3.20M | |
| $ 64.61M | $ 213.22M | $ 205.17M | $ 14.54M | $ 3.19M | |
| $ 42.59M | $ 37.67M | $ 32.70M | $ 16.14M | $ 11.42M | |
| Depreciation and Amortization | $ 23.00K | $ 22.00K | $ 17.00K | $ 10.00K | $ 8.00K |
| $ 22.05M | $ 175.57M | $ 199.26M | $ -670.00K | $ -10.98M | |
| $ 22.02M | $ 175.55M | $ 172.49M | $ -1.60M | $ -11.43M | |
| $ 16.91M | $ 7.39M | $ 32.65M | $ 916.00K | $ 439.00K | |
| $ 38.93M | $ 182.94M | $ 205.14M | $ -680.00K | $ -10.99M | |
| $ 30.44M | $ 142.04M | $ 157.08M | $ 184.00K | $ -7.79M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.24 | $ 1.11 | $ 1.24 | $ 0.00 | $ -0.07 |
| Diluted EPS | $ 0.23 | $ 1.09 | $ 1.20 | $ 0.00 | $ -0.07 |
| Weighted Average Shares Outstanding | 128.24M | 127.77M | 127.07M | 125.97M | 117.77M |
| Weighted Average Shares Outstanding (Diluted) | 130.77M | 130.78M | 130.77M | 128.91M | 117.77M |
Currency in AUD